+ Investor Call and Webcast

+ Investor Call and Webcast November 29, 2022 Creating an End-to-End Solution

for OGM & Transforming the Way the World Sees the Genome

Legal Disclaimer This presentation contains forward-looking statements.

Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects,"

"predicts," "potential," "goal" and similar expressions (including the negative thereof). Forward-looking statements in this presentation include, but are not limited to, statements regarding: (i) growth drivers and expected levels of our

organic growth; (ii) Bionano's ability to create an end-to-end solution for OGM; (iii) the benefits of isotachophoresis to the OGM workflow in comparison to other techniques and technologies; (iv) the benefits the acquisition may bring to

Bionano's partnerships; (v) expected adoption of OGM and the benefits the acquisition may have in promoting such adoption; (vi) the benefits of integrating Purigen's assets and personnel with Bionano's business; (vii) the anticipated closing of

the acquisition and the timing and expectations related thereto; (viii) Bionano's plans and expectations with respect to Purigen's business following the closing of the acquisition; (ix) the anticipated benefits of the transaction summarized in

this presentation, and our leadership position in the market; (x) our ability to stay in front of competitors' improvements in technologies; (xi) anticipated milestones; and (xii) other statements that are not historical facts. Actual results

or developments may differ materially from those projected or implied in these forward-looking statements. Forward-looking statements are based only on current information, assumptions and expectations, and involve a number of risks and

uncertainties relating to (i) our inability to integrate Purigen's business into our own; (ii) challenges inherent in developing, manufacturing and commercializing products; (iii) the timing and mix of customer orders among our products; (iv)

our ability to further deploy new products and applications and expand the markets for our technology platforms; (v) third parties' abilities to manufacture our instruments and consumables; (vi) the success of products competitive with our own;

(vii) our expectations and beliefs regarding future growth of the business and the markets in which we operate; (viii) the accuracy of our estimates; (ix) our ability to fund our operations; and (x) changes in our strategic and commercial

plans; and (xi) the application of generally accepted accounting principles which are highly complex and involve many subjective assumptions. We are under no duty to update any of these forward-looking statements after the date of this

presentation to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date

of this presentation. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this presentation. More information about these

and other statements, risks and uncertainties is contained in our filings with the U.S. Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings

subsequently made by us with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as

of such date. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, occurrence of future events or otherwise except as required by applicable law.

Bionano is Acquiring Technology that Can Enable it to Achieve its Goal of Creating

an End-to-End Solution for OGM DNA Labeling DNA Isolation Data Processing + + + + Data Analysis (2021) Every genome analysis begins at the sample .

Purigen Biosystems was formed in 2012 with technology exclusively licensed from

Stanford University Core technology, isotachophoresis (ITP), was developed in the Stanford Microfluidics Laboratory led by Dr. Juan Santiago Dr. Klint Rose, CSO and co-founder of Purigen, earned his PhD with Dr. Santiago at Stanford

University Purigen develops and commercializes systems based on ITP designed for rapid, efficient & high-performance automated RNA and DNA extraction 28 employees across functions including R&D, sales & marketing, manufacturing,

customer support and G&A Acquisition follows an extensive co-development program led by Bionano's COO, Mark Oldakowski, in which the Purigen team demonstrated the feasibility of isolating ultra-high molecular weight (UHMW) DNA on the

Ionic Purification System for use with Bionano's Saphyr instrument Purigen Biosystems Corporate Overview

Purigen's Ionic Purification System Commercially available platform for isolation

of DNA and RNA Uses isotachophoresis (ITP) for isolation and purification Addresses complex biological samples including those with low cell counts Purifies 8 samples in 1 hour with < 5 minutes of total hands-on time per sample in a fully

automated workflow, often with better results than currently available techniques (e.g., next-generation sequencing with FFPE samples) Current adoption is for variety of sample types and applications, including formalin-fixed paraffin

embedded (FFPE) tumor tissue Purigen's ITP technology Solution-based concentration approach to be used in development of kits for isolation of UHMW DNA Different from the techniques in routine use today which tend to rely on binding to a

matrix, washing and then removal from the matrix Results in higher yields and quality of DNA & RNA compared to column-based kits Ionic Purification System

Expected Strategic Benefits of the TransactionExpected to be a key step in

simplifying the end-to-end workflow for OGM - potential for fast, easy & robust routine use at scale ITP-based methods for UHMW DNA could potentially overcome limitations of current binding-based methods to further simplify sample

preparation for OGM and provide a common platform for OGM and next-generation sequencing (NGS) sample preparation Expands Bionano's technology portfolio for sample preparation & adds an automation platform designed for rapid, high

throughput sample preparation ITP is expected to be important in expanding the adoption of OGM by enabling Bionano to better address more sample types that are commonly used today throughout cancer research, genetic disease and other areas of

discovery research and cell bioprocessing Acquisition may complement partnership with Hamilton, which has developed a solution for the automation of Bionano's current isolation chemistry, by enabling Bionano to address more challenging sample

types including dilute samples or those with limited quantities of cells

Integration Plan Dr. Klint Rose, co-founder and CSO, will become a Bionano fellow

and lead development of ITP solutions for OGM Existing location for Purigen in Pleasanton, CA will remain in use Current Purigen employees are expected to join Bionano and become part of the appropriate functional team in Bionano The goal of

the integration plan is to: Fully support existing Purigen customers Expand the Ionic system installed base to customers who may or may not be OGM users to position Bionano as a key solution provider in molecular pathology and

cytogenomics Commercialize the Ionic system for OGM use with a variety of sample types

Up to $64M in total cash consideration $32M to be paid at closing, subject to

adjustment, and up to $32M to be paid in the future based on achievement of certain milestones Expected to close on or before December 8, 2022 Summary of Deal Terms

Questions & Answers Contact: R. Erik

Holmlin CEO eholmlin@bionanogenomics.com Chris Stewart CFO cstewart@bionanogenomics.com

November 29, 2022 + Transforming the Way the World Sees the Genome